TB survivors challenge patent to end J&J monopoly

Two tuberculosis survivors from Indian and South Africa have challenged Johnson and Johnson’s application to extend the patent over Bedaquiline, in order to keep it affordable for everyone. Bedaquiline is a drug used to treat multidrug-resistant tuberculosis (MDR-TB). MDR-TB is a condition where the TB bacteria has developed resistance to most antibiotic drugs. The J&J… Continue reading TB survivors challenge patent to end J&J monopoly

Blog
Academy
Community